Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors.

Oncotarget · 2017 · PMC5739624 · PMID 29285237

Europe PMC DOI

hedged sentence

0.0750

closest p · 1.5× alpha

0.0750

boldest claim

The sentences

did not reach statistical significancep=0.075so close (0.05 < p ≤ 0.1)

There was also a trend to a better PPOS in T790M-positive patients compared to the T790M-negative patients although it did not reach statistical significance (median 23.8 vs. 11.0 months, p=0.075, Supplementary Table 3 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.